Neurona Raises $102M to Advance Cell Therapy for Drug-Resistant Epilepsy

Published on Spencer Knight via LinkedIn

Neurona Therapeutics has secured $102 million to push forward its cell therapy NRTX-1001, which uses stem cell-derived GABAergic interneurons to treat drug-resistant epilepsy without the need for surgery. Early clinical data show an 80% positive response rate in patients.

Backed by investors including Fidelity, The Column Group, and Viking Global, the funding will also support future trials in Alzheimer’s disease, traumatic brain injury, and neuropathic pain. Spencer Knight calls this a major validation of cell therapy’s role in neurology.

Read the full post on LinkedIn:

👉 Spencer Knight: Neurona Raises Upsized $102M to Advance Cell Therapy for Epilepsy

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.